Zobrazeno 1 - 10
of 472
pro vyhledávání: '"Katsuyuki Hotta"'
Autor:
Hiroaki Matsuura, Hisao Higo, Tadahiro Kuribayashi, Akihiko Tamaoki, Takamasa Nakasuka, Mari Uno, Go Makimoto, Kiichiro Ninomiya, Masanori Fujii, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Nobuaki Miyahara, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura, Kadoaki Ohashi
Publikováno v:
Thoracic Cancer, Vol 15, Iss 17, Pp 1390-1394 (2024)
Abstract The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well‐established. We report
Externí odkaz:
https://doaj.org/article/d26d7a0f738c4648adc976251c979aaa
Autor:
Masahiro Yamashita, Hisao Higo, Nobuharu Fujii, Chiaki Matsumoto, Go Makimoto, Kiichiro Ninomiya, Masanori Fujii, Kammei Rai, Eiki Ichihara, Kadoaki Ohashi, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Nobuaki Miyahara
Publikováno v:
Respiratory Medicine Case Reports, Vol 51, Iss , Pp 102104- (2024)
A 56-year-old woman who received CD19 chimeric antigen receptor-T cell therapy for refractory diffuse large B-cell lymphoma developed severe coronavirus disease 2019 (COVID-19) and was treated with nirmatrelvir/ritonavir in April 2022. However, she e
Externí odkaz:
https://doaj.org/article/9c01c290090e46b7ac69d6db19592d95
Autor:
Go Makimoto, Atsushi Shimonishi, Kadoaki Ohashi, Kiichiro Ninomiya, Hisao Higo, Yuka Kato, Masanori Fujii, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura
Publikováno v:
Case Reports in Oncology, Vol 15, Iss 2, Pp 494-498 (2022)
Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel
Externí odkaz:
https://doaj.org/article/bfc3bf256a774f06afe80a674b5a7557
Autor:
Hisao Higo, Kadoaki Ohashi, Shuta Tomida, Sachi Okawa, Hiromasa Yamamoto, Seiichiro Sugimoto, Satoru Senoo, Go Makimoto, Kiichiro Ninomiya, Takamasa Nakasuka, Kazuya Nishii, Akihiko Taniguchi, Toshio Kubo, Eiki Ichihara, Katsuyuki Hotta, Nobuaki Miyahara, Yoshinobu Maeda, Shinichi Toyooka, Katsuyuki Kiura
Publikováno v:
Respiratory Research, Vol 23, Iss 1, Pp 1-10 (2022)
Abstract Background Tyrosine kinase activation plays an important role in the progression of pulmonary fibrosis. In this study, we analyzed the expression of 612 kinase-coding and cancer-related genes using next-generation sequencing to identify pote
Externí odkaz:
https://doaj.org/article/0d4105daf2044a01bae3d734d4fb44a5
Autor:
Hiromasa Yamamoto, Junichi Soh, Norihito Okumura, Hiroyuki Suzuki, Masao Nakata, Toshiya Fujiwara, Kenichi Gemba, Isao Sano, Takuji Fujinaga, Masafumi Kataoka, Yasuhiro Terazaki, Nobukazu Fujimoto, Kazuhiko Kataoka, Shinji Kosaka, Motohiro Yamashita, Hidetoshi Inokawa, Masaaki Inoue, Hiroshige Nakamura, Yoshinori Yamashita, Katsuyuki Hotta, Hiroshige Yoshioka, Satoshi Morita, Keitaro Matsuo, Junichi Sakamoto, Hiroshi Date, Shinichi Toyooka
Publikováno v:
PLoS ONE, Vol 18, Iss 5, p e0285273 (2023)
BackgroundIt is shown that the postoperative adjuvant chemotherapy for non-small cell lung cancer (NSCLC) was associated with survival benefit in an elderly population. We aimed to analyze the feasibility and efficacy of alternate-day S-1, an oral fl
Externí odkaz:
https://doaj.org/article/a63ce68f669540f0a4e6df4121d8faac
Autor:
Norihito Okumura, Junichi Soh, Hiroyuki Suzuki, Masao Nakata, Toshiya Fujiwara, Hiroshige Nakamura, Makoto Sonobe, Takuji Fujinaga, Kazuhiko Kataoka, Kenichi Gemba, Masafumi Kataoka, Katsuyuki Hotta, Hiroshige Yoshioka, Keitaro Matsuo, Junichi Sakamoto, Hiroshi Date, Shinichi Toyooka
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background The aim of this multicenter, randomized phase II study was to analyze the feasibility and safety of alternate-day S-1, an oral fluoropyrimidine, for adjuvant chemotherapy in patients with completely resected pathological stage I (
Externí odkaz:
https://doaj.org/article/9f7b3dfd6c3640f1a6868d1a9405ea53
Autor:
Yuanbin Chen, MD, PhD, Luis Paz-Ares, MD, PhD, Niels Reinmuth, MD, PhD, Marina Chiara Garassino, MD, Galina Statsenko, MD, Maximilian J. Hochmair, MD, Mustafa Özgüroğlu, MD, PhD, Francesco Verderame, MD, Libor Havel, MD, György Losonczy, MD, PhD, Nikolay V. Conev, MD, PhD, Katsuyuki Hotta, MD, PhD, MPH, Jun Ho Ji, MD, PhD, Stuart Spencer, MSc, Tapashi Dalvi, PhD, MPH, Haiyi Jiang, MD, Jonathan W. Goldman, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100330- (2022)
Introduction: In the phase 3 study involving the use of durvalumab with or without tremelimumab in combination with platinum-based chemotherapy in untreated extensive-stage SCLC (CASPIAN study), first-line durvalumab plus platinum-etoposide (EP) sign
Externí odkaz:
https://doaj.org/article/1c079ba625de443f80bdb5548364cf07
Autor:
Daijiro Harada, Hideko Isozaki, Toshiyuki Kozuki, Toshihide Yokoyama, Hiroshige Yoshioka, Akihiro Bessho, Shinobu Hosokawa, Ichiro Takata, Nagio Takigawa, Katsuyuki Hotta, Katsuyuki Kiura, Okayama Lung Cancer Study Group
Publikováno v:
Thoracic Cancer, Vol 12, Iss 5, Pp 643-649 (2021)
Abstract Background The efficacy of crizotinib treatment for recurring EML4‐ALK‐positive non‐small cell lung cancer (NSCLC) previously treated with alectinib is unclear. Based on our preclinical findings regarding hepatocyte growth factor/mesen
Externí odkaz:
https://doaj.org/article/969d0f50286c4d95ae3bc781ec7bc518
Autor:
Kazuya Nishii, Masaaki Inoue, Hideto Obata, Yutaka Ueda, Toshiyuki Kozuki, Masahiro Yamasaki, Tomonori Moritaka, Yoshikazu Awaya, Keisuke Sugimoto, Kenichi Gemba, Shoichi Kuyama, Hirohisa Ichikawa, Takuo Shibayama, Tetsuya Kubota, Masahiro Kodani, Daizo Kishino, Nobukazu Fujimoto, Nobuhisa Ishikawa, Yukari Tsubata, Tomoya Ishii, Kazunori Fujitaka, Katsuyuki Hotta, Katsuyuki Kiura
Publikováno v:
Thoracic Cancer, Vol 12, Iss 5, Pp 725-731 (2021)
Abstract Introduction Conventional cancer registries are suitable for simple surveillance of cancer patients, including disease frequency and distribution, demographics, and prognosis; however, the collected data are inadequate to clarify comprehensi
Externí odkaz:
https://doaj.org/article/39cc5a45f0b247419b90dcc755431024
Autor:
Yukari Tsubata, Shun Shinomiya, Koji Inoue, Nobuhisa Ishikawa, Ryota Saito, Kazuhisa Nakashima, Katsuyuki Hotta, Akinobu Hamada, Fumio Nagashima, Yuichi Ando, Satoshi Morita, Kunihiko Kobayashi, Takeshi Isobe
Publikováno v:
BMC Geriatrics, Vol 21, Iss 1, Pp 1-5 (2021)
Abstract Background In Japan, approximately half of all lung cancer patients are aged > 75 years, and the proportion of older patients is increasing. In older patients, it is necessary to consider comorbidities and concomitant drug use to ensure opti
Externí odkaz:
https://doaj.org/article/650317fb50ec46f4a5c04d7fc8843bc8